Steven Grant

35.1k citations

451 papers · 23.2k indexed · 2 hit papers · h-index 79

Hematology top 0.1%
- Acute Myeloid Leukemia Research 90
- Multiple Myeloma Research and Treatments 46
Molecular Biology top 0.1%
- Histone Deacetylase Inhibitors Research 104
- Cell death mechanisms and regulation 102
- Protein Degradation and Inhibitors 78
- Ubiquitin and proteasome pathways 52
Oncology top 0.2%
- Cancer-related Molecular Pathways 54
Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 43
Cancer Research top 0.5%

Co-authors: Paul Dent Yun Dai Mohamed Rahmani W. David Jarvis Roberto R. Rosato Paul B. Fisher Jorge A. Almenara Adly Yacoub
Cited by: Hematology Molecular Biology Oncology
Journals: Blood (79 papers)Molecular Pharmacology (31 papers)Cancer Biology & Therapy (26 papers)
Partner nations: United States Russia Canada

In The Last Decade

Steven Grant

446 papers receiving 22.8k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Steven Grant

Since Specialization

Citations

This map shows the geographic impact of Steven Grant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Grant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Grant more than expected).

Fields of papers citing papers by Steven Grant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Grant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Grant. The network helps show where Steven Grant may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Steven Grant, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Steven Grant Line = papers co-authored together Steven Grant links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax Clinical Cancer Research ·Falah Noori Saeed Al-dulaimi,小原明,Matsushita Itaru,宮田明義,Chelsea Blair,Kanika Sharma,Maciej Kmieciak,Mohamed Rahmani,Liang Zhou,Steven Grant	2023	9
2	NOTCH1 Represses MCL-1 Levels in GSI-resistant T-ALL, Making them Susceptible to ABT-263 Clinical Cancer Research ·Anahita Dastur,和雄我撫子,Carlotta Costa,Taciana Feitosa de Melo BRECKENFELD,August Williams,Joseph McClanaghan,Max Greenberg,Justine E. Roderick,Neha U. Patel,Pandey Mahendra Kumar,Ultan McDermott,Mathew J. Garnett,Jorge A. Almenara,Steven Grant,Kathryn Rizzo,Jeffrey A. Engelman,Michelle A. Kelliher,Anthony C. Faber,Cyril H. Benes	2018	16
3	Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells Cancer Research ·Mohamed Rahmani,Chelsea Blair,Mehmet Ali Nahit Sendur,Xin‐Yan Pei,Rebecca E. Parker,Maciej Kmieciak,Joel Johansson,Deepak Sampath,Andrea Ferreira‐Gonzalez,Steven Grant	2018	112
4	PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo Clinical Cancer Research ·Mohamed Rahmani,Mandy Mayo Aust,Arianna Gregg,Axel Buhl,Jonathan W. Friedberg,Steven Grant	2014	76
5	Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism Molecular Cancer Therapeutics ·Tri K. Nguyen,Steven Grant	2013	34
6	A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2 Clinical Cancer Research ·Beata Holkova,Jeffrey G. Supko,Matthew M. Ames,Joel M. Reid,Geoffrey I. Shapiro,Vinogradova A.I.,Viswanathan Ramakrishnan,Mary Beth Tombes,Aurora Herriott,Renee M. McGovern,Maciej Kmieciak,Ellen Shrader,Malcolm J. Lee,Heidi Sankala,Austin Doyle,James R. Wright,John D. Roberts,Steven Grant	2013	26
7	The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair Molecular Cancer Therapeutics ·Yun Dai,Shuang Chen,Maciej Kmieciak,Liang Zhou,Hui‐Yi Lin,Xin‐Yan Pei,Steven Grant	2013	46
8	CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies Cancer Research ·Shuang Chen,Yun Dai,Adi Domenico,A.S Fulginiti,Li Wang,Lora B. Kramer,P.J. Broadway,Daniella M. Schwartz,Yinchuan Guo,Gary Simmons,김명연,bulletproof,Paul Dent,Robert Z. Orlowski,Steven Grant	2012	46
9	Dual Inhibition of Bcl-2 and Bcl-xL Strikingly Enhances PI3K Inhibition-Induced Apoptosis in Human Myeloid Leukemia Cells through a GSK3- and Bim-Dependent Mechanism Cancer Research ·Mohamed Rahmani,Mandy Mayo Aust,Elisa Attkisson,D. Clive Williams,Andrea Ferreira‐Gonzalez,Steven Grant	2012	128
10	PLK1 Inhibitors Synergistically Potentiate HDAC Inhibitor Lethality in Imatinib Mesylate–Sensitive or –Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo Clinical Cancer Research ·Girija Dasmahapatra,Hiral Patel,Tri Q. Nguyen,Elisa Attkisson,Steven Grant	2012	22
11	HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells In Vitro and In Vivo Clinical Cancer Research ·Tri Nguyen,Yun Dai,Elisa Attkisson,Lora B. Kramer,孝治武政,Nguyen Nguyen,K. Nitta,Markus Müschen,Steven Grant	2011	70
12	Sorafenib Enhances Pemetrexed Cytotoxicity through an Autophagy-Dependent Mechanism in Cancer Cells Cancer Research ·Jose G. Machain Palacio,Margaret A. Park,Adly Yacoub,Hossein A. Hamed,Yong Tang,Nichola Cruickshanks,Patrick Eulitt,Stanko Vrabec,Gary Tye,Matthew E. Burow,Paul B. Fisher,Richard G. Moran,Kenneth P. Nephew,Steven Grant,Paul Dent	2011	97
13	Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca2+- De novo Ceramide-PP2A-Reactive Oxygen Species–Dependent Signaling Pathway Cancer Research ·Margaret A. Park,Clint Mitchell,Guo Zhang,Adly Yacoub,Jeremy C. Allegood,Dieter Häussinger,Roland Reinehr,Andrew C. Larner,Sarah Spiegel,Paul B. Fisher,Christina Voelkel‐Johnson,Besim Öğretmen,Steven Grant,Paul Dent	2010	86
14	Sorafenib Activates CD95 and Promotes Autophagy and Cell Death via Src Family Kinases in Gastrointestinal Tumor Cells Molecular Cancer Therapeutics ·Margaret A. Park,Roland Reinehr,Dieter Häussinger,Christina Voelkel‐Johnson,Besim Öğretmen,Adly Yacoub,Steven Grant,Paul Dent	2010	74
15	17-Allylamino-17-Demethoxygeldanamycin and MEK1/2 Inhibitors Kill GI Tumor Cells via Ca2+-Dependent Suppression of GRP78/BiP and Induction of Ceramide and Reactive Oxygen Species Molecular Cancer Therapeutics ·Teneille Walker,Clint Mitchell,Margaret A. Park,Adly Yacoub,Mohamed Rahmani,Dieter Häussinger,Roland Reinehr,Christina Voelkel‐Johnson,Paul B. Fisher,Steven Grant,Paul Dent	2010	16
16	Mechanism by Which Mcl-1 Regulates Cancer-Specific Apoptosis Triggered by mda-7/IL-24, an IL-10–Related Cytokine Cancer Research ·Rupesh Dash,Joanna E. Richards,Zhao-zhong Su,Sujit K. Bhutia,Belal Azab,Mohamed Rahmani,Girija Dasmahapatra,Adly Yacoub,Paul Dent,Igor P. Dmitriev,David T. Curiel,Steven Grant,Maurizio Pellecchia,John C. Reed,Devanand Sarkar,Paul B. Fisher	2010	65
17	Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation Clinical Cancer Research ·Guo Zhang,Margaret A. Park,Clint Mitchell,Hossein A. Hamed,Mohamed Rahmani,Aditi Pandya Martin,David T. Curiel,Adly Yacoub,Martin R. Graf,Ray Lee,John D. Roberts,Paul B. Fisher,Steven Grant,Paul Dent	2008	101
18	Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95 Molecular Cancer Therapeutics ·Margaret A. Park,Guo Zhang,Clint Mitchell,Mohamed Rahmani,Hossein A. Hamed,Michael P. Hagan,Adly Yacoub,David T. Curiel,Paul B. Fisher,Steven Grant,Paul Dent	2008	41
19	Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells Clinical Cancer Research ·Yun Dai,Shuang Chen,Lora B. Kramer,Luis Eduardo Pariente Zorrilla,Paul Dent,Steven Grant	2008	68
20	The Multikinase Inhibitor Sorafenib Potentiates TRAIL Lethality in Human Leukemia Cells in Association with Mcl-1 and cFLIPL Down-regulation Cancer Research ·Roberto R. Rosato,Jorge A. Almenara,G Rawlings,Steven Grant	2007	99

About Steven Grant

Steven Grant is a scholar working on Hematology, Genetics, Molecular Biology, Oncology and Cell Biology, having authored 451 papers that have together received 23.2k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (104 papers), Cell death mechanisms and regulation (102 papers), Acute Myeloid Leukemia Research (90 papers), Protein Degradation and Inhibitors (78 papers), Cancer-related Molecular Pathways (54 papers), Ubiquitin and proteasome pathways (52 papers), Multiple Myeloma Research and Treatments (46 papers) and Chronic Lymphocytic Leukemia Research (43 papers). The work is most often cited by research in Hematology (3.6k citations), Molecular Biology (16.7k citations), Oncology (6.3k citations), Genetics (1.7k citations) and Cancer Research (2.3k citations). Steven Grant has collaborated with scholars based in United States, Russia and Canada. Frequent co-authors include Paul Dent, Yun Dai, Mohamed Rahmani, W. David Jarvis, Roberto R. Rosato, Paul B. Fisher, Jorge A. Almenara, Adly Yacoub, Xin‐Yan Pei and Richard Kolesnick. Their work appears in journals such as Blood, Molecular Pharmacology, Cancer Biology & Therapy, Cancer Research and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact